IJCEP Copyright © 2007-All rights reserved.
Int J Clin Exp Pathol 2013;6(6):1095-1102

Original Article
Mir-375 enhances ruthenium-derived compound Rawq01 induced cell death in human
ovarian cancer

Xiaowen Shao, Wenjie Mei Wenhao Weng, Jinlong Qin, Jianhong Zhou, Jie Liu, Jiajing Cheng

Department of Obstetrics and Gynecology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, 200072, P.R.
China; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, P.R. China; Department of Laboratory Medicine,
Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, 200072, P.R. China. Equal contributors.

Received March 10, 2013; Accepted April 27, 2013; Epub May 15, 2013; Published June 1, 2013

Abstract: Ovarian cancer is one of the most common gynecological malignancies. Limited efficacy of cytotoxic chemotherapy is a key obstacle
in the treatment of advanced ovarian cancer. This study aimed to investigate whether Mir-375 enhances Rawq01 (a ruthenium derived
compound) induced cell death in ovarian cancer. Methods: Three human ovarian cancer cell lines were selected, and independently treated
with Rawq01+mir-375 and Rawq01+control. MTT assay and flow cytometry were performed to detect the growth of ovarian cancer cells.
Western blot was carried out to determine the expression of apoptotic associated proteins. In addition, ovarian cancer xenografts were
established to explore whether mir-375 increased the in vivo chemosensitivity of ovarian cancer cells to RAWQ01. Results: Over-expression of
mir-375 sensitized the ovarian cancer cells to RAWQ01. Mir-375 enhanced the in vitro sensitivity of ovarian cancer cells to RAWQ01 by inducing
apoptosis. Mir-375 also increased the in vivo chemosensitivity of ovarian cancer cells to RAWQ01. Conclusion: Mir-375 can enhance Rawq01
induced cell death in human ovarian cancer both in vitro and in vivo. (IJCEP1303023).

Keywords: Ovarian cancer, mir-375, ruthenium derived compound, Rawq01

Address correspondence to: Dr. Jiajing Cheng, Department of Obstetrics and Gynecology, Shanghai Tenth People’s Hospital, Tongji
University School of Medicine, Shanghai, 200072, P.R. China. E-mail: chen321314@hotmail.com